DAROpenNetwork (D) fluctuated by 71.1% in 24 hours: driven by surging trading volume and signs of whale accumulation
Bitget Pulse2026/04/26 16:02Volatility Overview
In the past 24 hours, D's price hit a low of $0.01169 and a high of $0.020, currently quoted at $0.0157, with a fluctuation range of 71.1%. Trading volume surged to approximately $79.66 million, up 5.4% from the previous day, with a market cap of about $10 million and a significant sign of net capital inflow (high volume/market cap ratio).
Brief Analysis of the Abnormality
• 24h trading volume spiked 5.4% to $79.66 million, accompanied by a rapid price increase from the lows, indicating liquidity sweep and accumulation activities by capital.
• On-chain community monitoring detected whale accumulation signals, such as multiple large buy-ins driving a short-term pump (price once +10.3%), with no official announcements yet highly active trading.
Market Opinions and Outlook
The mainstream sentiment in the community is cautiously optimistic. Traders expect a pullback to the $0.009-$0.011 support zone after the pump to confirm the subsequent uptrend, but warn of high BND risk and potential corrections. Analysts advise not to FOMO, to pay attention to low timeframe reversal signals and whale movements.
Note: This analysis is automatically generated by AI based on publicly available data and on-chain monitoring, for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Phase III trial failure for new heart drug causes Novo Nordisk shares to plunge: increasing reliance on weight-loss drugs, R&D transformation faces new test
Novo Nordisk announced on Friday that its cardiovascular drug ziltivekimab failed to reduce the risk of major cardiovascular events in a phase III clinical trial involving 6,300 patients, causing its stock price to plummet by 8.7% in a single day. The market had held high expectations for ziltivekimab, hoping the drug would establish a second growth curve beyond diabetes and weight-loss medications.
Ondo Perps trading volume surpasses $300 million, ONDO targets $0.47 breakout
Financial Gravity Is Broken: 5 Altcoins Worth Holding as Altseason 2026 Enters Full Hyperdrive

Hyperliquid holds key $53 support as daily trading volume reaches $13.5 billion